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INTRODUCTION
The sodium iodide symporter (NIS) mediates iodide uptake in thyroid follicular cells and provides a mechanism for effective radioiodide treatment of residual, recurrent, and metastatic thyroid cancers. The objective of the proposed research is to test the hypothesis that expression of exogenous hNIS in prostatic tissue will enable radioiodide to localize and ablate residual prostate cancer following prostatectomy, such that recurrence and metastasis of the disease can be prevented. The specific aims of this project are to: (1) confirm metastatic progression to distant lymph nodes and lungs following subcutaneous inoculation of rats with MATLyLu prostatic adenocarcinoma cells expressing hNIS; (2) investigate whether radioiodide therapy will prevent metastases and/or prolong survival in rats bearing subcutaneous MATLyLu tumors that express hNIS; (3) determine the expression level of hNIS required to elicit selective radioiodide-mediated killing of MATLyLu-hNIS prostatic adenocarcinoma cells in vivo; and, (4) restrict hNIS expression in prostatic tissue under transcriptional regulation of prostate-specific promoter. The sodium/iodide symporter (NIS) is a membrane transport with NIS induction. The cAMP and phosphoinositide-3 kinase glycoprotein normally expressed in the thyroid gland and lac-(P13K) signaling pathways are associated with NIS up-regutatingmammary gland. NIS is a target for radioiodide imaging lation. We showed that activation of P13K alone is sufficient to and therapeutic ablation of thyroid carcinomas and has the increase NIS expression and radioiodide uptake in MCF-7 potential for similar use in breast cancer treatment. To facilhuman breast cancer cells, whereas cAMP stimulation initate NIS-mediated radionuclide therapy, it is necessary to creases NIS promoter activity and NIS mRNA levels but is not identify signaling pathways that lead to increased NIS exsufficient to increase radioiodide uptake. This study is the pression and function in breast cancer. We examined NIS exfirst to demonstrate that NIS expression is induced by cAMP pression in mammary tumors of 14 genetically engineered and/or P13K in breast cancer both in vivo and in vitro. B REAST CANCER IS one of the leading causes of cancer routine clinical examination, which together have decreased in women in the United States, with more than 181,000 mortality by 25-30% in women over 50 yr old. However, newly diagnosed cases and in excess of 44,000 cancer-related monitoring recurrence and metastases by frequent physical deaths annually (1) . Several specific genetic mutations and examination in breast cancer patients has not been successful environmental factors leading to an increased risk of breast in changing the clinical course, and most women with metcancer have been elucidated in recent years. Conventional astatic carcinoma will eventually die from the disease. Theretreatment modalities for breast cancer include radical masfore, detection and treatment of recurrent and metastatic tectomy, lumpectomy with radiotherapy, systemic hormone breast cancer is of high clinical importance. modulating therapy (tamoxifen and raloxifene), and chemoThe sodium/iodide symporter (NIS) is a transmembrane therapy (1, 2) . Diagnosis is currently made at an earlier stage glycoprotein most commonly studied in the context of the of the disease due to increased use of mammography and thyroid gland, in which it mediates active transport of iodide (I-) from the systemic circulation into thyroid follicular cells. Abbreviations: 8-Br-cAMP, 8-Bromoadenosine-cAMP; ChT, cholera NIS forms the basis of radioiodide treatment for thyroid toxin; Cox, cyclooxygenase; ddH 2 0, double-distilled water; FBS, fetal cancer by facilitating targeted radioiodide uptake and subsebovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; c GEM, genetically engineered mice; hCG, human chorionic gonadotroquent destruction of residual and/or metastatic neoplastic cells pin; H&E, hematoxylin and eosin; IBMX, 3-isobutyl-l-methylxanthine; after thyroidectomy (3, 4) . Additionally, NIS-expressing thy-MMTV, mouse mammary tumor virus; NIS, sodium/iodide symporter; roid tumors can be imaged using nuclear scintigraphy, im-PGE2, prostaglandin E2; P13K, phosphoinositide-3 kinase; PyMT, polyproving detection of residual, recurrent, or metastatic lesions. oma virus middle T antigen; SV40, Simian virus 40; TBS, Tris-buffered saline; tRA, trans-retinoic acid.
BODY
In addition to the thyroid gland, the salivary glands, gas-JCEM is published monthly by The Endocrine Society (http://www. tric mucosa, lacrimal system, placenta, and lactating mamendo-society.org), the foremost professional society serving the enmary gland express NIS and thus have the capacity to acdocrine community.
tively accumulate iodide (5 Turku, Turku, Finland). The transgene, which was introduced into an FVB/N background, consisted of a 579-bp cDNA segment of the hCGP
The use of genetically engineered mice (GEM) has greatly gene driven by a 1.2-kb ubiquitin C promoter (8) . Transgenic female increased understanding of mammary tumorigenesis, offerUbi-hCGP mice were obese, underwent precocious puberty, and had ing a convenient system for studying the interaction of speabnormal estrous cycles leading to infertility. Females had abnormally cific genetic manipulations with external factors. Tumors from high serum estradiol levels until 2 months of age, at which time it
Her-2/neu and v-Ha-ras transgenic mice have been reported to returned to normal. Serum progesterone, testosterone, and prolactin levels gradually increased from the age of 4-6 months until 12 months.
express NIS and could be imaged using scintigraphy (5) . Re " Glycoprotein a-subunit promoter driving LHI/C-terminal peptide fusion gene.
(Ohio State University, Columbus, OH). The transgene consisted of the rance, CA) or 1 ýLM prostaglandin E2 (PGE2; Sigma, St. Louis, MO) for PyMT gene open reading frame driven by the promoter of the MMTV.
24 or 48 h before radioiodide uptake assay. In experiments requiring Mammary tumorigenesis was evident by the age of 5 wk, although very treatment with tRA, 3-isobutyl-l-methylxanthine (IBMX), 8-bromoadearly lesions of atypical ductular hyperplasia sometimes preceded neoenosine-cAMP (8-Br-cAMP), or cholera toxin (ChT; all from Sigma), plasia. Histologically, tumors were solid to cystic, multicentric, often charcoal-stripped culture medium was used (equal parts DMEM and poorly differentiated, invasive, and widely metastatic (10, 11) .
Ham's F12, 5% charcoal-stripped FBS, and 1% penicillin/streptomycin). Tissue sections from MMTV-neu transgenic mice were acquired from When culturing MCF-7 cells treated with PGE2 or MCF-7 stable clones Dr. Emma Di Carlo (G. d'Annunzio University, Chieti, Italy), and tissue expressing pBpuro, v-Ha-ras, or P13K, cells were maintained in 89% sections from MMTV-c-neu transgenic mice were obtained from Dr.
RPMI 1640 with glutamine (Invitrogen), 10% FBS, and 1% penicillin/ William Kisseberth (The Ohio State University, Columbus, OH). MMTVstreptomycin. PC C1 3 rat thyroid cells were cultured in 91% Coon's neu mice from G. d'Annunzio University were created by insertion of modified F-12 medium with 5% calf serum, 1% 200 mm glutamine, 1% the transgene, consisting of the MMTV promoter driving expression of 1 m sodium bicarbonate, 1% penicillin/streptomycin, and 1% of a sixthe activated rat neu oncogene, into a BALB/c background strain (12) .
hormone mixture (1 nM TSH, 10 Ag/ml insulin, 10 ng/ml somatostatin, Widespread atypical hyperplasia of small lobular ducts and lobules was 5 [ig/ml transferrin, 10 nM hydrocortisone, and 10 ng/ml glycyl-Lalready evident in mammary tissue at the third week of age, progressing histidyl-L-lysine acetate; all from Sigma). to lobular carcinoma in situ by the 10th to 11th week and finally to multiple invasive carcinomas at approximately 20 wk of age, which DNA constructs involved all 10 mammary glands by the age of 33 wk. MMTV-c-neu mice from The Ohio State University were created by insertion of the trans-NIS promoter-luciferase reporter gene constructs, 144-bp hNMSp and gene, consisting of the MMTV promoter driving expression of the un-2.9-kb hNISp, were engineered using the PGL 2 B vector as described by activated rat c-neu protooncogene, into an FVB/N background strain Ryu et al. (14) . Recombinant retroviruses encoding v-Ha-ras, P13K p Greenville, NC) as described by Davis et al. (15) . mammary tissue was sectioned to 5 Am thickness and affixed to glass slides. Deparaffinization and rehydration were performed as follows:
Luciferase assay slides were submerged in 100% xylene for three repetitions of 5 min each, followed by submersion into 100% ethanol for two repetitions of 2 min
Approximately 1 x 105 MCF-7 cells were seeded in each well of a each, 95% ethanol for 2 min, and 70% ethanol for two repetitions of 2 min 6-well plate. After 24 h, cells were transfected with human NIS proeach. Next, slides were gently washed in double-distilled water (ddH 2 0) moters (2.9-kb hNISp, 144-bp hNISp, or PGL 2 C control vectors) using for 2 min. Endogenous peroxidase activity was blocked by soaking slides Lipofectamine (Invitrogen). The culture medium was then changed to in 3% hydrogen peroxide in methanol for 15 min. After gently washing 5% charcoal-stripped medium, and cells were treated with IBMX (10 MM) slides in ddH 2 0, antigen retrieval was performed by dipping slides in and ChT (10 ng/ml) for 24 h. Cells were harvested, and luciferase assays steaming ddH 2 0 and placing them into steaming citric acid buffer (ciwere performed using a luciferase assay kit (Promega, Madison, WI) and trate, sodium citrate, and ddH 2 0) for 30 min. After antigen retrieval, luminometer (Lumat; PerkinElmer, Boston, MA). As a positive control, slides were cooled by soaking in lukewarm ddH 2 0 and then rinsed in the PGL 2 -C control vector with the Simian virus 40 (SV40) promoter Tris-buffered saline [TBS; 3% 5 N NaCl, 1% 1 m Tris (pH 8.0), and 96%
showed high basal activities but no further activation by IBMX+ChT ddH 2 0] with gentle agitation. Next, slides were placed in a humidified treatment. Normalization of transfection efficiency was determined by chamber and blocked at 4 C overnight using 2% BSA in TBS. The cotransfecting cells with the plasmid pCH110 (SV40-LacZ). Within each following day, BSA was removed by aspiration and rabbit antirat NIS treatment group, luciferase activity was normalized to 3-galactosidase primary antibody, which cross-labels mouse NIS (PA716, a kind gift activity. from Dr. Bernard Rousset, Institut National de la Santd et de la Recherche M~dicale, Lyon, France; diluted 1:1000 in 1% BSA) was immediately Quantitative real-time PCR applied to slides, which were then incubated in a humidified chamber at room temperature for 1 h. Negative control slides were incubated with Quantitative real-time PCR assay was performed as described by our 1% BSA alone. After 1 h, slides were washed with TBS to remove residual laboratory (16) . Briefly, 5 X 105 MCF-7 cells were seeded in normal primary antibody. Horseradish peroxidase-conjugated goat antirabbit culture medium in 35-mm plates. Medium was changed to charcoalsecondary antibody (Bio-Rad Laboratories, Hercules, CA) was diluted stripped MCF-7 medium 1 d before treatment with 8-Br-cAMP or IBMX 1:250 in 1% BSA and applied to slides for 20 min incubation in a huand ChT. RNA was isolated 24 h after treatment using TRIzol reagent midified chamber at room temperature. Slides were rinsed in TBS to (Invitrogen). One microgram of RNA was used for the reverse tranremove residual secondary antibody. Antigen-antibody complexes were scription reaction. Two microliters of cDNA template were used for detected by incubation of tissue sections with chromagen DAB (Dako, quantitative real-time PCR, which used the human NIS dual-probe Carpinteria, CA) for 5 min in a dark chamber at room temperature. Slides quantification method. For glyceraldehyde-3-phosphate dehydrogenase were rinsed in ddH 2 0 three times with gentle agitation, counterstained (GAPDH) normalization, 236 bp human GAPDH was amplified by PCR with Gill's hematoxylin (Fisher Scientific, Pittsburgh, PA) for 30 sec, using two primers: GAPDH-F1 (TTC ACC ACC ATG GAG AAG GC) dipped in running lukewarm tap water, placed in clarifier for 1 min, and GAPDH-R1 (GGC ATG GAC TGT GGT CAT GA). The amplified rinsed a second time in running lukewarm tap water, and dipped in a DNA fragment was cloned into the TA cloning vector, maxiprepped bluing agent (1% NH40H). Dehydration was performed by dipping (Qiagen, Valencia, CA) and used as the standard for SYBR Green I slides in a progression of 70% ethanol, 95% ethanol, 100% ethanol, and quantitative real-time PCR. The data were presented as a fold increase 100% xylene. Slides were then air dried and coverslipped. over control after NIS mRNA levels were normalized with GAPDH mRNA levels.
Cell culture
Radioiodide uptake assay MCF-7 cells were maintained in medium consisting of equal parts DMEM and Ham's F12, 10% fetal bovine serum (FBS), and 1% penicillin/ Radioiodide uptake assay was performed essentially as in La Perle et streptomycin (Invitrogen, Carlsbad, CA) and kept in a 37 C incubator al. (17) . (Fig. 2) . We also showed that PGE2 treatment induces radioiodide uptake (Fig. 3) response element is present in these promoter regions.
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The importance of signal transduction through P13K was investigated using MCF-7/PI3K stable clones. ChT (ngfml) unit had greater than 4-fold increase in radioiodide uptake, compared with empty vector-expressing cells (Fig. 7) . Stable 
Discussion
16000
This study is the first to demonstrate the importance of "( 14000 cAMP and P13K signaling in NIS regulation in the context of 1h 12000 the mammary gland. We showed that activation of P13K alone is sufficient to increase NIS expression and radioiodide Vx I** i Iuptake in MCF-7 human breast cancer cells, whereas cAMP E 8000 stimulation increases NIS promoter activity and NIS mRNA S6000 levels but is not sufficient to increase radioiodide uptake (see
18 and our unpublished data).
S4000
We found that MMTV-Cox-2 and Ubi-hCGP3 transgenic 
18
j tRA were used as a positive control. **, P < 0.01; *** P < 0.001. 'a
16-1
tivator, was not sufficient to increase radioiodide uptake (see elements are present in these regions. CTL, Untreated control. **, P < Transient transfection of mutant rasV12S35, which prefer-0.01; **** P < 0.0001.
entially interacts with the downstream effector Raf-1, abolished NIS expression in TSH-stimulated Wistar rat thyroid that treatment of MCF-7 cells with PGE2 induced cAMP (WRT) cells (32, 33). The rasV12C40 mutant, which interacts levels by more than 10-fold over untreated controls. Treatprimarily with P13K, maintained NIS expression. Our findment with hCG also increased NIS expression in JAr human ing of increased radioiodide uptake in MCF-7/PI3K stable choriocarcinoma cells via interaction with the LH/CG reclones demonstrates that overexpression of PI3K alone is ceptor (25) and in rat FRTL-5 thyroid cells via interaction sufficient to induce NIS function in MCF-7 cells. It is interwith the TSH receptor (26) .
esting to note that Lin et al. (11) discovered frequent inducWe demonstrated that treatment of MCF-7 cells with comtion of neu expression in PyMT mammary tumors, which was pounds that increase intracellular cAMP levels (IBMX, ChT, confirmed in our study (data not shown). Thus, NIS inducand 8-Br-cAMP) led to a significant increase in NIS mRNA tion in the mammary tumors of PyMT mice is potentially a levels and NIS promoter activity ( 
C.C.C.).
Up-regulation of signaling pathways in Her-2/neu-, PyMT-, and Cox-2-induced tumors is potentially more representaReferences tive of the human disease than is up-regulation by marked [191] [192] [193] [194] [195] [196] [197] [198] In this study, we found cAMP and P13K to be of critical In this study provides several significant ad- and 9-cis-rehnoic acid were the only compounds known to Radioiodide uptake activity mediated by the human Na+]Imalignant rat thyroid cell lines and primary cultures of norsymporter (hNIS) in thyroid follicular cells is the basis for mal human thyroid and human follicular adenoma cells were effective "saI therapy in thyroid cancer. However, radioiodide investigated. We found that the relative promoter activity of therapy is not effective in patients with thyroid cancer disTg vs. CMV is critical for the efficacy of the Cre/loxP system. playing low or absent hNIS expression. This study assessed
In cells with weak Tg promoter activity, coinfection of rAdthe Cre/loxP system for enhancing thyroid-targeted hNIS exTg-Cre and rAd-CMV-loxP-hNIS induced higher hNIS exprespression driven by the thyroglobulin (Tg) promoter. The folsion than single infection of rAd-Tg-hNIS. Finally, Tg prolowing three recombinant adenoviruses (rAd) were constructmoter activity was partially restored in malignant thyroid ed: rAd-Tg-hNIS drives hNIS expression by the The thyroglobulin (Tg) promoter has been extensively roid carcinoma (1) . DTC (papillary and follicular carcistudied for its potential use in transcriptionally targeted noma) comprises about 85-90% of all thyroid malignancies thymidine kinase suicide gene therapy of thyroid cancer (2). Most patients with DTC can be effectively treated with (10) (11) (12) . The Tg promoter is an ideal candidate to confer surgery followed by radioiodide-131 ablation and have a thyroid-targeted gene expression due to its high level of relatively good prognosis (3, 4) . However, approximately thyroid-specific transcriptional activity. Unfortunately, one third of patients with DTC and all patients with anait has been reported that the Tg promoter activity is weaker plastic carcinoma cannot benefit from radioiodine therapy in thyroid carcinomas than in normal thyroid tissues (13). due to reduced or absent ability to concentrate iodide (2, A possible way to enhance Tg promoter-driven gene 5). It has been reported that the loss of radioiodine accuexpression in thyroid carcinomas is the application of the mulation in thyroid cancer is due, in part, to decreased Cre/loxP system. Several reports have demonstrated expression of the Na'/I-symporter (NIS), the key molthe ability of the Cre/loxP system to enhance transcripecule that mediates the active uptake of iodide into thyroid tionally targeted suicide gene expression using the Tg tissues (6-9). Thus, NIS gene transfer to restore and/or promoter or the carcinoembryonic antigen promoter in increase radioiodide uptake (RAIU) activity represents a thyroid or gastrointestinal cancer cells, respectively (11, promising means to improve the effectiveness of radioio-14-17). dine therapy in patients with non-iodine-avid thyroid canIn this paper, we investigated and compared two difcers. The objective of this study is to investigate the effiferent adenoviral systems in providing thyroid-specific human NIS (hNIS) expression (Fig. 1A) . The first system Abbreviations: CMV, Cytomegalovirus; DTC, differentiated thyroid involves a single adenovirus, in which hNIS expression is carcinoma; FBS, fetal bovine serum; HBSS, Hanks' balanced salt soludriven by the Tg promoter (rAd-Tg-hNIS). The second tion; MOI, multiplicity of infection; NIS, Na+/I-symporter; rAd, recombinant adenovirus; RAIU, radioiodide uptake; Tg, thyroglobulin. system involves two adenoviruses, one in which the Tg JCEM is published monthly by The Endocrine Society (http://www. promoter drives Cre recombinase expression (rAd-Tgendo-society.org), the foremost professional society serving the enCre) and another in which the cytomegalovirus (CMV) docrine community, promoter is separated from the hNIS gene by two loxP (Cre K rAd-CMV-loxP-hNIS is designed to express hNIS gene under the The plasmid pSh-Tg-hNIS was constructed as follows. A Kpnl-Pmel strong CMV promoter only after Cre recombinase excises the GFP-Zeo fragment containing the hNIS gene was excised from pSh-CMV-hNIS fusion gene. The ends of the Zeo and hNIS genes both contain a stop (20) and cloned into the pShuttle vector. The 2.0-kb bovine Tg procodon (*). B, Increased hNIS expression will be induced in cells with moter (located from -2036 to +9 nucleotide relative to the transcripan active Tg promoter by the Tg-Cre/CMV-loxP-hNIS system. Cre tional start site) was then released as a SpeI-KpnI fragment from recombinase excises GFP-Zeo fusion gene between the two loxP sites pSh-Tg-PTC3 and inserted upstream of the hNIS gene to generate as a covalently closed circle, leaving one loxP site behind and allowing pSh-Tg-hNIS. transcription of hNIS driven by the strong CMV promoter.
The plasmid pSh-Tg-Cre was constructed as follows. The Cre recombinase gene and 588 bp of polyA sequence from the PBS185 vector were recombinase recognition) sites (rAd-CMV-loxP-hNIS).
released as a SpeI (blunt-ended by T 4 DNA polymerase)-XbaI fragment and replaced the hNIS gene in pSh-Tg-hNIS. The extra 588-bp polyA Coinfection of these two adenoviruses into thyroid cells fragment was then removed by MluI/XbaI digestion to generate results in Cre expression, which then excises an intervenpSh-Tg-Cre.
ing DNA sequence bearing a stop codon between the two
The plasmid pSh-CMV-!oxP-hNIS was constructed as follows. The loxP sites, thereby allowing hNIS expression under control loxP-GFP-Zeo-loxP fragment from the pCMV-13-4-REV vector was subof the strong CMV promoter (Fig. 113) . Here, we show that the relative promoter activity of Tg vs. CMV is critical for rAd-Tg-hNIS, rAd-Tg-Cre, and rAd-CMV-loxP-hNIS were produced the ability of the Cre/loxP system to enhance thyroidand purified as described previously (20,21). The titers of adenoviruses targeted hNIS expression. Thus, in cells with weak Tg were determined by plaque formation in 293 cells and expressed in promoter activity, coinfection of rAd-Tg-Cre and rAdpfu/ml.
CMV-IoxP-hNIS induced higher hNIS expression than single infection of rAd-Tg-hNIS.
Detection of hNIS protein by Western blot analysis
Cells were plated in 100-mm dishes. When cells became 70-80% Materials and Methods confluent, they were infected with various adenoviruses at the inCell lines and stable clones dicated multiplicity of infection (MOI) for 2 h. Forty-eight hours postinfection, cells were harvested for Western blot analysis as deCos-7 monkey kidney cells were maintained in DMEM supplemented scribed previously with minor modification (22) . Briefly, the memwith 10% fetal bovine serum (FBS). FRTL-5 differentiated normal rat brane fractions of the cells were subjected to 7.5% SDS-PAGE. The thyroid cells (kindly provided by Dr. Leonard D. Kohn, Ohio University, proteins were transferred to nitrocellulose membrane (Schleicher & Athens, OH) were cultured in Coon's modified Ham's F-12 medium, Schuell, Keene, NH). The membrane was incubated with the affinitysupplemented with 5% calf serum and six hormone (6H) mixture as purified hNIS antibody (1:1500), which recognizes the COOH termidescribed previously (18). Malignant FRTC cells were derived from nus of hNIS protein, for 1 h at room temperature, followed by in- x-ray film.
--
MW
Detection of NIS function by RAIU assay -4-90 kDa
Cells were seeded in 24-well plates. When cells became 70-80% 60 kDa confluent, they were incubated with various adenoviruses at the indicated MOI for 2 h. Forty-eight hours postinfection, RAIU assay was performed as described previously (20). Briefly, cells were incubated B with 2 ACi Na 125I for 30 min at 37 C with 5% CO 2 . Cells were then washed with cold HBSS twice, and the radioiodide taken up by the cells Cos-7 FRTL-5 FRTL-5 was released by 95% ethanol for 20 min at room temperature. The rAd-Tg-Cre + + radioactivity was counted by a y-counter (Packard Instruments, DownrAd-CMV-|oxP-hNIS + + + ers Grove, IL). Experiments were performed in triplicate. 
MW
Generation of functional rAds: rAd-Tg-hNIS, rAd-Tg-Cre, and rAd-CMV-loxP-hNIS
Three rAds, rAd-Tg-hNIS, rAd-Tg-Cre, and rAd-CMVexpression occurred when cells were administered with a loxP-hNIS, were constructed as described in Materials and 1:1 ratio of rAd-Tg-Cre vs. rAd-CMV-IoxP-hNIS (data not Methods. To verify the function of these three rAds, various shown). Because hNIS antibodies do not detect endogeadenoviruses were infected into FRTL-5 rat normal thynous rNIS in FRTL-5 cells, we were able to compare the roid cells or Cos-7 monkey kidney cells. The level of hNIS expression levels of hNIS induced by the designated adprotein in infected cells was detected by Western blot enovirus. Our data showed that both Tg-hNIS and Tganalysis. As expected, rAd-Tg-hNIS can only express hNIS Cre/CMV-loxP-hNIS induced hNIS expression in FRTL-5 protein in Tg-expressing FRTL-5 cells but not in Cos-7 cells cells; however, the level of hNIS protein in FRTL-5 cells (Fig. 2A) . Similarly, hNIS expression was detected only in coinfected with the Tg-Cre/CMV-IoxP-hNIS system was FRTL-5 cells but not in Cos-7 cells after coinfection with significantly higher than that in cells infected with rAdrAd-Tg-Cre and rAd-CMV-loxP-hNIS (Fig. 2B) . The cells Tg-hNIS alone (Fig. 3A) . It is difficult to quantify the infected with rAd-CMV-loxP-hNIS alone did not induce relative hNIS expression levels induced by one system vs. hNIS expression, indicating that Cre recombinase is reanother because different exposure times were required to quired for hNIS expression in the dual virus system optimize the detection of hNIS protein. (Fig. 2B) . It is notable that although FRTL-5 cells express
As shown in Fig. 3B , the RAIU activity in FRTL-5 cells endogenous rat NIS (rNIS), our hNIS antibodies do not was significantly increased by infection of rAd-Tg-hNIS cross-react with rNIS (see lane 3 in Fig. 2B ). To compare the abilities of the Tg-hNIS and Tg-Cre/ only slightly higher than that in cells infected with rAd-CMV-loxP-hNIS systems to mediate hNIS expression and Tg-hNIS alone (Fig. 3B) . Thus, it appears that not all infunction, we infected FRTL-5 cells with either rAd-Tgduced hNIS resulted in increasing RAIU activity in in- 
Cre and rAd-CMV-loxP-hNIS
I*xP4hmNS (M10125:25)
Malignant FRTC thyroid cells are reported to express low Adenovirus Infection levels of Tg mRNA (10, 23) , which is similar to less differ- ( Fig. 3B) .
alone served as a control for endogenous hNIS.
tively high level of iodide uptake, which is due to the exgeted thyroid cells. The investigated cells were divided into pression of endogenous hNIS protein in the normal primary four experimental groups. Cells were either transfected with culture.
Tg/pGL 2 B or CMV/pGL 2 B to determine Tg or CMV promoter activity by luciferase assay. Simultaneously, cells were Enhanced hNIS expression and RAIU activity in human either infected with rAd-Tg-hNIS alone (MOI = 20) or cointhyroid follicular adenoma primary culture coinfected with fected with the Tg-Cre/CMV-loxP-hNIS system (MOI = 10: rAd-Tg-Cre and rAd-CMV-loxP-hNIS 10) to determine RAIU activity. As shown in Fig. 7 , when the A human thyroid follicular adenoma primary culture was relative promoter activity of Tg vs. CMV is 1:5 in P14 FRTL-5 derived from a thyroid follicular adenoma that was cold on cells, Cre/loxP is not effective to further enhance Tg-targeted the radioiodide scan 3 months before surgery, which implies hNIS-mediated RAIU activity. In comparison, when Tg prothe absent or weak hNIS expression or function in the cells moter activity was much weaker than CMV promoter activcompared with surrounding normal cells. To reintroduce ity in P20 FRTL-5 (the relative promoter activity of Tg vs. hNIS expression and evaluate the efficacy of the Tg-Cre/ CMV is 1:333), the Cre/loxP system was more effective in CMV-loxP-hNIS system in this follicular adenoma, cultured increasing RAIU activity than Tg-hNIS alone. In primary cells were either infected with rAd-Tg-hNIS alone (MOI = cultures of human thyrocytes, in which the relative promoter 20) or coinfected with rAd-Tg-Cre and rAd-CMV-loxP-hNIS activity of Tg vs. CMV was about 1:1600 or 1:1500, the Tg-(MOI = 10:10). Western blot analysis and RAIU assay were
Cre/CMV-loxP-hNIS system was very effective in enhancing performed to examine hNIS expression and hNIS function.
Tg-targeted hNIS-mediated RAIU activity (Fig. 7) . In addiAgain, as shown in Fig. 6 , hNIS expression levels and the tion, it was interesting to note that the CMV promoter acincrease of RAIU activity induced by Tg-Cre/CMV-loxPtivity varied among different cells (data not shown). NIS-based gene therapy to patients, it is important to restrict
In this paper, we hypothesize that the Tg-Cre/CMV-loxP-NIS expression to targeted cells to avoid unwanted side hNIS system is able to enhance thyroid-targeted hNIS exeffects in nontargeted tissues. For patients after total thypression. The hypothesis is mainly based on the assumption roidectomy, NIS expression may be restricted to residual that CMV promoter activity is much stronger than Tg prothyroid cancer using Tg as a tissue-specific promoter. Howmoter activity in targeted cells. Thus, the relative promoter ever, Tg promoter activity is generally much weaker than activity of Tg vs. CMV in the targeted cells will be vital for that of a constitutive viral promoter. Thus, the Tg-Cre/CMVthe efficacy of Tg-Cre/CMV-loxP-hNIS. Experiments were loxP-hNIS system may be superior to a Tg-hNIS system to performed to correlate the relative promoter activity of Tg vs.
induce hNIS expression in thyroidal tissues. In this study, we CMV with the efficacy of Tg-Cre/CMV-loxP-hNIS in tarshowed that the Cre/loxP system was effective in enhancing However, for cells with low or absent enculture, and human thyroid follicular adenoma primary culdogenous NIS, defects in cell surface trafficking of hNIS are ture. In addition, we showed that the efficacy of Tg-Cre/ suspected. The proper and efficient cell surface trafficking CMV-loxP-hNIS is dependent upon the relative promoter has been shown to play an important role in the functional activity of Tg vs. CMV. Thus, for thyroid cancers with strong expression of hNIS in thyroid cells (9, 29, 30) . Thus, possible Tg promoter activity, a Tg-hNIS system may be sufficient to defects in cell surface trafficking of hNIS in malignant cells confer high levels of hNIS expression to improve radioiodide remain a real challenge for hNIS-based gene therapy. therapy. For thyroid cancers with weak Tg promoter activity, To apply Tg-targeted NIS gene therapy, Tg promoter acCre/loxP is an attractive system to enhance Tg-targeted NIS tivity in cancer cells needs to be sufficient, if not maximized. expression. However, for thyroid cancers with negligible Tg
In this study, we showed that forced expression of Pax-8 into promoter activity, strategies to increase Tg promoter activity FRTC cells slightly increased Tg promoter activity and inmust also be used to confer Tg-targeted hNIS expression.
duced detectable hNIS expression. Thyroid transcription facImmortalized FRTL-5 cells have been known to display tor 1 (TTF-1) has also been shown to reactivate the Tg prodifferent characteristics with age or transformation. Serially moter in thyroid carcinoma cells (31, 32). Therefore, forced passaged FRTL-5 cells are reported to dedifferentiate and expression of both TTF-1 and Pax-8 may further facilitate the lose Tg expression (27). This is consistent with our data that efficacy of Tg-targeted NIS gene therapy. In addition, a tanthe aged P20 FRTL-5 cells had weaker Tg promoter activity dem repeat of the minimal Tg promoter has been shown to than the young P14 FRTL-5 cells (Fig. 7A) . Similarly, deinduce much higher thymidine kinase expression in transcreased Tg promoter activity has been reported in FRTC duced thyroid cells than the single Tg promoter did (33). tumor of the 12th generation compared with the third genThus, it is desirable to generate a composite Tg promoter eration (23) . Although forced expression of Pax-8 in FRTC yielding the highest thyroid-specific promoter activity. Furcells increased Tg promoter activity and allowed Tg-targeted thermore, the efficiency of Cre-directed site-specific recomhNIS expression/function, the increase of RAIU activity in bination could be enhanced by facilitating Cre nuclear lo-FRTC/Pax-8 cells coinfected with Tg-Cre/CMV-loxP-hNIS calization (34) . Finally, the efficacy of the Cre/loxP system was not high enough to justify further animal study. We also may be further improved by dually expressing Tg-Cre and evaluated the effects of Cre/loxP system on FTC133 human CMV-loxP-hNIS in a single adenovirus to avoid inefficient thyroid carcinoma cells (28). However, FTC133 cells exhibcoinfection of two adenoviruses. ited undetectable Tg promoter activities and did not induce
In conclusion, the Tg-Cre/CMV-loxP-hNIS system can RAIU activity by the Tg-hNIS system or the Cre/loxP system significantly enhance thyroid-targeted hNIS expression and (data not shown). Therefore, a non-iodine-avid tumorigenic induce RAIU activity in thyroid cells with weak Tg promoter thyroid tumor cell line, yet with some retained Tg promoter activity. We showed that the relative promoter activity of Tg activity, will be essential to examine the efficacy of the Crevs. CMV is crucial for the efficacy of the Cre/loxP system. loxP system to increase Tg-targeted hNIS expression/funcThus, before NIS-based gene therapy, Tg promoter activity tion in preclinical animal models.
should be evaluated, for example, by measuring serum Tg It is interesting to note that the extent of increased RAIU levels upon TSH stimulation in patients. activity does not appear to be proportional to the extent of induced hNIS expression in all cells studied. For cells withIntroduction ulation. The rNUE contains two paired domain-containing transcription factor (Pax-8) binding sites and a degenerate T HE SODIUM/IODIDE SYMPORTER (NIS) is a transmembrane cAMP response element (CRE) sequence, and stimulates glycoprotein that mediates active iodide transport into transcription in a thyroid-specific and thyrotropin (TSH)-thyroid follicular cells (1) . The active iodide uptake is not cAMP-responsive manner (9) . Based on sequence homology only the first and rate-limiting step for thyroid hormone to rNUE (69% identity), the hNIS upstream enhancer (hNUE) biosynthesis, but also the basis for the use of radioiodide was identified and shown to confer thyroid-specific and (131I) in diagnosis and treatment of differentiated thyroid TSH-cAMP-responsive transcriptional activity (12) (13) (14) . The cancers (2) (3) (4) (5) . Because of the physiologic and therapeutic sig-296 bp hNUE is located at -9348 to -9054 nt relative to the nificance of NIS in thyroid cells, the regulatory mechanisms ATG site and contains a Pax-8 binding site and a CRE-like underlying NIS gene expression have attracted much atten-sequence. tion. Several groups have attempted to elucidate the tranRecently, mouse NIS (mNIS) cDNA was cloned and found scriptional regulation of rat NIS (rNIS) and human NIS to exhibit 92% identity with rNIS cDNA, while only 78% (hNIS) genes by characterizing their corresponding 5'-flank-identity with hNIS cDNA (15) (16) (17) (18) . Using the genomic walking regions (6) . The minimal region for rNIS promoter ac-ing method, a 3.2 kb genomic DNA fragment corresponding tivity is localized to -291 to -135 nt relative to the ATG site to the 5'-flanking region of the mNIS gene was cloned and (7-9), while the hNIS minimal promoter is localized to -443 characterized. The 3.2 kb 5'-flanking region of mNIS shares to -395 nt relative the ATG site (10) (11) . It has been shown 68% identity with that of rNIS, yet shares little similarity with that the NIS minimal promoter alone is not sufficient to con-that of hNIS. Based on sequence homology, the mNIS upfer thyroid-specific transcriptional activity. Among the cis-stream enhancer (mNUE) was localized to the region beacting elements identified, the rNIS upstream enhancer tween -3042 and -2809 nt relative to the ATG site. The (rNUE), located at -2495 to -2264 nt relative to the ATG mNUE shares 94.4% identity with rNUE and enhances transite, represents the most important aspect of NIS gene reg-scription in a thyroid-specific and TSH-responsive manner. Materials and Methods (lmU/mL), insulin (10 /±g/mL), hydrocortisone (10 nM),
Cloning of 3.2 kb mNIS genomic DNA fragment
transferrin (5 Ag/mL), and L-glycyl-histidyl-lysine (2 ng/mL) (7). Rat-i rat embryonic fibroblast cells were maintained in Based on the published sequence of mNIS cDNA, two DMEM supplemented with 10% fetal bovine serum (FBS). mNIS gene-specific reverse primers, mNISGSPI (5'-GCA Cells were seeded in 6-well plates. When cells became CCT GCA CAG CCG A CA TGA AGC TA-3') and mNIS-50%-60% confluent, calcium phosphate transfection was per-GSP2 (5'-CAG CAT GGT CGC GAA CAC GCC GTA GT-3'), formed using 3 /g of promoter-luciferase reporter DNA conwere designed, corresponding to +220 to +195 nt and +72 struct and 0.2 /tg of 13-galactosidase DNA construct. The to + 47 nt relative to the putative ATG site, respectively. With DNA precipitates were replaced with fresh medium 6 hours these two primers and the adapter primers provided by the later for FRTL-5 cells or 20 hours later for Rat-I cells. Cells mouse genomeWalker TM kit (Clontech, Palo Alto, CA), PCR were washed with PBS and lysed with 80 AL of the lysis reactions were performed using platinum Taq DNA poly-buffer 48 hours post-transfection in a luciferase assay kit merase (Gibco, Invitrogen, Carlsbad, CA). The modified pro-(Promega, Madison, WI). The luciferase and 3-galactosidase cedure of primary touchdown PCR includes 7 cycles of de-assays were carried out as described previously (7). For lunaturation at 94°C for 2 seconds, annealing and extension at ciferase assay, 20 /L of cell lysate was used. For p-gal assay, 70'C for 3 minutes, then 37 cycles of denaturation at 94'C 7 ttL of lysate was used with the Galacto-Light chemilumifor 2 seconds, annealing and extension at 65°C for 3 minutes, nescent f3-galactosidase reporter assay kit (Tropix, Applied and finally an extension at 65°C for 4 minutes. The secondary Biosystems, Foster City, CA). Experiments were performed touchdown PCR includes 5 cycles of denaturation at 94*C in duplicate. for 2 seconds, annealing and extension at 70'C for 3 minutes,
The investigation of the effects of TSH on (enhancer) /prothen 24 cycles of denaturation at 94°C for 2 seconds, an-moter constructs in FRTL-5 cells was performed as described nealing and extension at 65°C for 3 minutes, and finally an previously (9) . The transfected FRTL-5 cells were cultured in extension step at 65°C for 4 minutes. Two DNA fragments, starvation medium supplemented with 0.2% calf serum for 1.8 kb and 3.1 kb in length, containing the 5'-flanking region 72 hours and then incubated in the 4H medium (without inof the mNIS gene were amplified from Dral and PvuII mouse sulin and TSH) or with 4H + TSH (without insulin) for an genomeWalker libraries, respectively. These two DNA frag-additional 72 hours. The cells were harvested, and luciferase ments were cloned into the TA cloning vector pCR2.1 (In-and/3-galactosidase assays were performed. vitrogen), named 1.8 kb/pCR2.1 and 3.1 kb/pCR2.1, and their nucleotide sequences were analyzed. Based on the se-Computer-assisted identification of potential transcription quence determined from the 3.1 kb DNA fragment, two re-binding sites in the 5'-flanking regions of NIS verse primers, mNISGSP3 (5'-GTG TCT AGA AGA AGG TGT TGG GCC TC-3') and mNISGSP4 (5'-GAA GCA ATC Potential transcription factor binding sites in the 5'-flank-AGT GTC CAG AGA CTG TC-3'), corresponding to -2832 ing regions of mNIS, rNIS, and hNIS genes were analyzed to -2807 nt and -2940 to -2915 nt relative to the ATG site, using the MatInspector Release Professional 6.2 program respectively, were designed for another round of genomic (Genomatix, Munich). A core similarity, defined by the conwalking. The resulting 350 bp DNA fragment from the DraI secutive highest conserved positions in the matrix, was set library was cloned into pCR2.1 vector to generate 350 to be larger than 0.8. A matrix similarity took into account bp/pCR2.1 for nucleotide sequence analysis.
all bases over the whole matrix and was set as optimized, which minimized false positives and false negatives for each Plasmids individual matrix (19).
1.8 kb/pGL 2 B was constructed by inserting the 1.8 kb KpnI-EcoRV fragment from 1.8 kb/pCR2.1 vector into the Kpnl-HindIII sites of pGL 2 B, which is a promoterless lucif-Isolation and sequence analysis of the erase vector. The mNIS/pGL 2 B DNA construct was subse-3.2 kb mNIS 5'-flanking region quently generated by removing the 969 bp Spel-Mlul fragTwo gene-specific primers, mNISGSP1 and mNISGSP2, ment from 1.8 kb/pGL 2 B and then removing the putative were derived from the published 5' end of the mNIS cDNA ATG site by digesting with NcoI enzyme, followed by Mung sequence (17). After one round of genomic walking, the 1.8 Bean nuclease treatment (New England Biolabs).
kb DNA fragment from the Dral library and the 3.1 kb DNA The putative mNUE DNA fragment was amplified from fragment from the PvuII library were obtained and semouse genomic DNA by PCR using a pair of primers, quent termined 220 bp mNIS ORF sequence matches the published (7) (8) (9) (10) (11) . A potential non-canonical TATA box (AATAAAT) is mouse cDNA sequence. The 3.2 kb 5'-flanking region of the identified at -124 to -118 nt relative to the ATG site, 21 nt mNIS gene shares 68% identity with that of the rNIS gene. upstream of the putative mNIS transcriptional start site. Sim-A .....
Higher homology regions with about 80% identity are found ilarly, the TATA box is located 21 nt upstream of the puta-U within the proximal and distal regions of NIS' 5'-flanking tive rNIS transcriptional start site and 23 nt upstream of the sequence. In contrast, the 5'-flanking region of mNIS shares putative hNIS transcriptional start site (7) (8) (9) (10) (11) . Potential tranlittle similarity with that of hNIS, except in the minimal pro-scription factor binding sites in the 5'-flanking regions of moter and hNUE regions. The putative transcriptional start mNIS and rNIS genes were analyzed by the MatInspector site of mNIS is located around -97 nt upstream of the ATG Release Professional 6.2 program. A total of 204 and 279 posite, based on sequence homology with rNIS. In comparison, tential transcription factor binding sites were identified in the transcriptional start site of rNIS is located around -98 the 3.2 kb 5'-flanking regions of rNIS and mNIS, respectively. nt relative to the ATG site, while the transcriptional start site Among these transcriptional binding sites, 63 were shared of hNIS has been mapped to -375 nt relative to the ATG site by both mNIS and rNIS. Interestingly, the MatInspector Re- . Thus, the sequence 8 binding sites, which are located in the NUE region of mNIS surrounding the GRE-like sequence is well conserved beand rNIS. This may be due to underdeveloped consensus se-tween mNUE and rNUE, yet it is completely divergent bequences of the Pax-8 site in the software. tween mNUE/rNUE and hNUE. A stretch of 234 bp between -3042 and -2809 nt relative
to the ATG site, which shares 94.4% identity with rNUE, was Functional analysis of mNIS promoter and mNUE (F Iidentified as the putative mNUE (Fig. 2) . The putative mNUE --also contains two Pax-8 binding sites and a cAMP response
To investigate the promoter activity of mNIS, a 650 bp element (CRE)-like sequence based on sequence homology DNA fragment corresponding to the immediate 5'-flanking to rNUE. Using the MatInspector software, both mNUE and region of mNIS was inserted into a promoterless luciferase rNUE were found to contain a Tax/CREB binding site, while reporter construct pGL 2 vestigate the functionality of the mNUE, a 233 bp of PCR-responsive, mNIS/pGL 2 B and mNUE-mNIS/pGL 2 B DNA amplified DNA fragment corresponding to the putative constructs were transfected into FRTL-5 thyroid cells in the mNUE was inserted into mNIS/pGL 2 B to generate mNUE-absence or presence of TSR. The enhancer activity of mNUE mNIS/pGL 2 B. The promoter activities of these two DNA on mNIS promoter activity was dramatically stimulated by constructs were evaluated in the FRTL-5 rat thyroid cells and TSR (almost eightfold) (Fig. 4) . In contrast, TSR did not in-* FF 3ý the Rat-i rat fibroblast cells. As shown in Fig. 3 , mNIS/ crease luciferase activity of cells transfected with mNIS/ '-...' SpGL 2 B conferred significant promoter activity in both thy-pGL 2 B. roid and non-thyroid cells, compared to the promoterless pGL 2 B. Thus the minimal promoter of mNIS is located within Discussion the 650 bp of the 5'-flanking region, and the minimal promoter activity is not thyroid-specific. We also showed that NIS expression in thyroid tissues is not only of physiothe enhancer activity of mNUE is thyroid-specific, as mNIS logic significance but also of clinical significance. While some promoter activity was increased by mNUE more than three-thyroid cancers have defects in NIS cell surface trafficking fold in FRTL-5 thyroid cells but not in Rat-i fibroblasts. To (5), many thyroid tumors have decreased NIS expression. determine whether the enhancer activity of mNUE is TSR Studying the mechanisms underlying NIS regulation in thy- roid tissue will help to devise strategies for increasing or two Pax-8 binding sites. Thus, the second Pax-8 binding site restoring 13 1 1-concentrating activity in thyroid cancers, almay play an important role in activating rNUE activity in lowing effective 1311 therapy. Furthermore, most factors af-non-thyroid cells. It is also important to note that while both fecting iodide uptake activity in thyroid tissues appear to the sequence surrounding the CRE-like sequence and the regulate NIS expression at the transcriptional level (6) . Since transcription factors binding to the CRE-like sequence apthe mouse is a useful preclinical animal model to screen for pear to be very different between hNUE and r/mNUE (9, important factors that increase NIS expression in thyroid tis- [13] [14] , the NUE in all three species exerts enhancer activity sues, we cloned and characterized the 3.2 kb 5'-flanking rein a thyroid-specific and TSH-responsive manner. Based on gion of mNIS in this study. The 3.2 kb 5'-flanking region of sequence homology to rNUE, we anticipate that mNUE can mNIS shares 68% identity with that of rNIS, yet shares little also be activated in non-thyroid cells by exogenous Pax-8 similarity with the corresponding region of hNIS. Based on and the transcription factors binding to the CRE-like sesequence homology to rNIS, the putative mNIS transcripquence of mNUE may be similar to those for rNUE. tional start site is mapped to -97 nt relative to the ATG site, Among the common 63 transcriptional binding sites idenin contrast to -375 nt in hNIS. Furthermore, mNUE, local-tified in the 5'-flanking region of rNIS and mNIS, several are ized to the region between -3042 and -2809 nt relative to of particular interest. The concurring increase in AP2 exthe ATG site, shares higher homology with rNUE (94.4% pression and decrease in NIS expression in thyroid tumors identity) than with hNUE (67.8% identity). Finally, we dem-suggests that AP2 may play a role in downregulating NIS onstrated that mNUE enhances mNIS transcription in a thy-expression in thyroid tumors (21). In v-ras-Ki transformed roid-specific and TSH-responsive manner.
thyroid cells, NIS expression was significantly decreased Despite their sequence divergence, both hNUE and rNUE (22) , while AP1 activity was drastically increased (23) . Thus, activities require a CRE-like sequence and Pax-8 binding API may be involved in downregulating NIS expression. sites (9, (12) (13) (14) . However, rNUE can be activated by exogeSince Maf nuclear oncoprotein recognizes sequences related nous Pax-8 in both thyroid and non-thyroid cells (9) , while to an API site and forms heterodimers with both Fos and hNUE can only be activated by exogenous Pax-8 in thyroid Jun (24) , Maf may have a regulatory role in NIS expression. cells (12) (13) . It is of interest to note that hNUE contains only RREB-1 has been reported to play a role in Ras and Raf sigone Pax-8 binding site, yet both rNUE and mNUE contain nal transduction in medullary thyroid cancer cells (25) . 
